Patient leaflet - Comirnaty KP.2 30 micrograms/dose Dispersion for injection, single dose vial
1. What Comirnaty KP.2 is and what it is used for
Comirnaty KP.2 is a vaccine used for preventing COVID-19 caused by SARS-CoV-2.
Comirnaty KP.2 30 micrograms/dose dispersion for injection, single dose vial is given to adults and adolescents from 12 years of age and older.
The vaccine causes the immune system (the body’s natural defences) to produce antibodies and blood cells that work against the virus, so giving protection against COVID-19.
As Comirnaty KP.2 does not contain the virus to produce immunity, it cannot give you COVID-19.
The use of this vaccine should be in accordance with official recommendations.
2. What you need to know before you receive Comirnaty KP.2
Comirnaty KP.2 should not be given
- if you are allergic to the active substance or any of the other ingredients of this medicine (listed in section 6)
Warnings and precautions
Talk to your doctor, pharmacist or nurse before you are given the vaccine if:
- you have ever had a severe allergic reaction or breathing problems after any other vaccine injection or after you were given this vaccine in the past.
- you are feeling nervous about the vaccination process or have ever fainted following any needle injection.
- you have a severe illness or infection with high fever. However, you can have your vaccination if you have a mild fever or upper airway infection like a cold.
- you have a bleeding problem, you bruise easily or you use a medicine to prevent blood-clots.
- you have a weakened immune system, because of a disease such as HIV infection or a medicine such as corticosteroid that affects your immune system.
There is an increased risk of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) after vaccination with Comirnaty (see section 4). These conditions can develop within just a few days after vaccination and have primarily occurred within 14 days. They have been observed more often after the second vaccination, and more often in younger males. The risk of myocarditis and pericarditis seems lower in children ages 5 to 11 years compared with ages 12 to 17 years. Most cases of myocarditis and pericarditis recover. Some cases required intensive care support and fatal cases have been seen. Following vaccination, you should be alert to signs of myocarditis and pericarditis, such as breathlessness, palpitations and chest pain, and seek immediate medical attention should these occur.
As with any vaccine, Comirnaty KP.2 may not fully protect all those who receive it and it is not known how long you will be protected.
The efficacy of Comirnaty KP.2 may be lower in people who are immunocompromised. If you are immunocompromised, you may receive additional doses of Comirnaty KP.2. In these cases, you should continue to maintain physical precautions to help prevent COVID-19. In addition, your close contacts should be vaccinated as appropriate. Discuss appropriate individual recommendations with your doctor.
Children
Comirnaty KP.2 30 micrograms/dose dispersion for injection, single dose vial is not recommended for children aged under 12 years.
There are paediatric formulations available for infants aged 6 months and above and children below 12 years of age. For details, please refer to the Package Leaflet for other formulations.
The vaccine is not recommended for infants aged under 6 months.
Other medicines and Comirnaty KP.2
Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines or have recently received any other vaccine.
Comirnaty KP.2 may be given at the same time as a flu vaccine.
In adults 18 years of age and older, Comirnaty KP.2 may be given at the same time as a pneumococcal conjugated vaccine (PCV).
In adults 18 years of age and older, Comirnaty KP.2 may be given at the same time as a respiratory syncytial virus (RSV) vaccine.
In older adults 65 years of age and older, Comirnaty KP.2 may be given at the same time as a high dose flu and an RSV vaccine.
Pregnancy and breast-feeding
If you are pregnant or think you may be pregnant, tell your doctor, nurse or pharmacist before you receive this vaccine.
No data are available yet regarding the use of Comirnaty KP.2 during pregnancy. However, a large amount of information from pregnant women vaccinated with the initially approved Comirnaty vaccine during the second and third trimester have not shown negative effects on the pregnancy or the newborn baby. While information on effects on pregnancy or the newborn baby after vaccination during the first trimester is limited, no change to the risk for miscarriage has been seen. Comirnaty KP.2 can be used during pregnancy.
No data are available yet regarding the use of Comirnaty KP.2 during breast-feeding. However, no effects on the breastfed newborn/infant are anticipated. Data from women who were breast-feeding after vaccination with the initially approved Comirnaty vaccine have not shown a risk for adverse effects in breastfed newborns/infants. Comirnaty KP.2 can be used while breast-feeding.
Driving and using machines
Some of the effects of vaccination mentioned in section 4 (Possible side effects) may temporarily affect your ability to drive or use machines. Wait until these effects have worn off before you drive or use machines.
3. How Comirnaty KP.2 is given
Comirnaty KP.2 is given as an injection of 0.3 mL into a muscle of your upper arm.
You will receive 1 injection, regardless whether you have received a COVID-19 vaccine before.
If you were previously vaccinated with a COVID-19 vaccine, you should not receive a dose of Comirnaty KP.2 until at least 3 months after the most recent dose.
If you are immunocompromised, you may receive additional doses of Comirnaty KP.2.
If you have any further questions on the use of Comirnaty KP.2, ask your doctor, pharmacist or nurse.
4. Possible side effects
Like all vaccines, Comirnaty KP.2 can cause side effects, although not everybody gets them.
Very common side effects: may affect more than 1 in 10 people
- injection site: pain, swelling
- tiredness, headache
- muscle pain, joint pain
- chills, fever
- diarrhoea
Some of these side effects were slightly more frequent in adolescents 12 to 15 years than in adults.
Common side effects: may affect up to 1 in 10 people
- nausea
- vomiting (‘very common’ in pregnant women 18 years of age and older and in immunocompromised individuals 12 to 18 years of age)
- injection site redness (‘very common’ in immunocompromised individuals 12 years of age and older)
- enlarged lymph nodes (more frequently observed after a booster dose)
Uncommon side effects: may affect up to 1 in 100 people
- feeling unwell, feeling weak or lack of energy/sleepy
- arm pain
- insomnia
- injection site itching
- allergic reactions such as rash or itching
- decreased appetite
- dizziness
- excessive sweating, night sweats
Rare side effects: may affect up to 1 in 1 000 people
- temporary one sided facial drooping
- allergic reactions such as hives or swelling of the face
Very rare side effects: may affect up to 1 in 10 000 people
inflammation of the heart muscle (myocarditis) or inflammation of the lining outside the heart
(pericarditis) which can result in breathlessness, palpitations or chest pain
Not known (cannot be estimated from the available data)
- severe allergic reaction
- extensive swelling of the vaccinated limb
- swelling of the face (swelling of the face may occur in patients who have had facial dermatological fillers)
a skin reaction that causes red spots or patches on the skin, that may look like a target or
“bulls-eye” with a dark red centre surrounded by paler red rings (erythema multiforme)
- unusual feeling in the skin, such as tingling or a crawling feeling (paraesthesia)
- decreased feeling or sensitivity, especially in the skin (hypoaesthesia)
- heavy menstrual bleeding (most cases appeared to be non-serious and temporary in nature)
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via a Yellow card. Reporting forms and information can be found at https://coronavirus-yellowcard.mhra.gov.uk/or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store Comirnaty KP.2
Keep this medicine out of the sight and reach of children.
The following information about storage, expiry and use and handling is intended for healthcare professionals.
Do not use this medicine after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of that month.
Store in freezer at -90 °C to -60 °C.
Store in the original package in order to protect from light.
The vaccine will be received frozen at -90 °C to -60 °C. Frozen vaccine can be stored either at -90 °C to -60 °C or 2 °C to 8 °C upon receipt.
Single dose vials: When stored frozen at -90 °C to -60 °C, 10-vial packs of single dose vials of the vaccine can be thawed at 2 °C to 8 °C for 2 hours or individual vials can be thawed at room temperature (up to 30 °C) for 30 minutes.
Thawed (previously frozen) vials: Once removed from the freezer, the unopened vial may be stored and transported refrigerated at 2 °C to 8 °C for up to 10 weeks; not exceeding the printed expiry date (EXP). The outer carton should be marked with the new expiry date at 2 °C to 8 °C. Once thawed, the vaccine cannot be re-frozen.
Prior to use, the unopened vials can be stored for up to 12 hours at temperatures between 8 °C and 30 °C.
Thawed vials can be handled in room light conditions.
Do not use this vaccine if you notice particulates or discolouration.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information
What Comirnaty KP.2 contains
The active substance of COVID-19 mRNA Vaccine (nucleoside modified) is called cemivameran.
- A single dose vial contains 1 dose of 0.3 mL with 30 micrograms cemivameran each.
The other ingredients are:
- ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315)
- 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)
- 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC)
- cholesterol
- trometamol
- trometamol hydrochloride
- sucrose
- water for injections
What Comirnaty KP.2 looks like and contents of the pack
The vaccine is a white to off-white dispersion (pH: 6.9 - 7.9) provided in a single dose vial of 1 dose in a 2 mL clear vial (type I glass), with a rubber stopper and a grey flip-off plastic cap with aluminium seal; or
Pack size: 10 vials
Marketing Authorisation Holder
BioNTech Manufacturing GmbH
An der Goldgrube 12
55131 Mainz
Germany
Phone: +49 6131 9084-0
Fax: +49 6131 9084-2121
service@biontech.de
Manufacturers
BioNTech Manufacturing GmbH
An der Goldgrube 12
55131 Mainz
Germany
BioNTech Manufacturing GmbH
Kupferbergterrasse 17 - 19
55116 Mainz
Germany
Pfizer Manufacturing Belgium NV
Rijksweg 12
Puurs-Sint-Amands, 2870
Belgium
For any information about this medicine, please contact: Medical Information, Pfizer Ltd, Walton Oaks, Dorking Road, Tadworth, Surrey, KT20 7NS. Telephone 01304 616161.
This leaflet was last revised in 04/2026.
Ref: bCY (KP.2) 30 mcg SDV 8_0
------------------------------------------------------------------------------------------------------------------------
The following information is intended for healthcare professionals only:
Administer Comirnaty KP.2 intramuscularly as a single dose of 0.3 mL regardless of prior COVID-19 vaccination status.
For individuals who have previously been vaccinated with a COVID-19 vaccine, Comirnaty KP.2 should be administered at least 3 months after the most recent dose of a COVID-19 vaccine.
Additional doses may be given to individuals who are severely immunocompromised.
Traceability
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Handling instructions prior to use
Verify that the vial has a grey plastic cap and the product name is Comirnaty KP.2
30 micrograms/dose dispersion for injection, single dose vial (12 years and older).
If the vial has another product name on the label, please make reference to the Summary of
Product Characteristics for that formulation.
If the vial is stored frozen it must be thawed prior to use. Frozen vials should be transferred to an environment of 2 °C to 8 °C to thaw. Ensure vials are completely thawed prior to use.
- Single dose vials: A 10-vial pack of single dose vials may take 2 hours to thaw.
- Upon moving vials to 2 °C to 8 °C storage, update the expiry date on the carton.
- Unopened vials can be stored for up to 10 weeks at 2 °C to 8 °C; not exceeding the printed expiry date (EXP).
- Alternatively, individual frozen vials may be thawed for 30 minutes at temperatures up to 30 °C.
Prior to use, the unopened vial can be stored for up to 12 hours at temperatures up to 30 °C.
Thawed vials can be handled in room light conditions.
Preparation of 0.3 mL doses
- Gently mix by inverting vials 10 times prior to use. Do not shake.
- Prior to mixing, the thawed dispersion may contain white to off-white opaque amorphous particles.
- After mixing, the vaccine should present as a white to off-white dispersion with no particulates visible. Do not use the vaccine if particulates or discolouration are present.
Check whether the vial is a single dose vial or a multidose vial and follow the applicable handling instructions below:
Single dose vials
- Withdraw a single 0.3 mL dose of vaccine.
- Discard vial and any excess volume.
Disposal
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.